Please provide your email address to receive an email when new articles are posted on . Proton pump inhibitors with histamine 2 receptor antagonists reduced all-cause mortality in patients with ...

Phathom will showcase its growing leadership in GI through multiple engagements with the medical and scientific community, including a product theater presentation highlighting VOQUEZNA ® (vonoprazan) ...

The FDA approved vonoprazan (Voquezna) as a daily treatment for heartburn associated with non-erosive gastroesophageal reflux disease (GERD) in adults. GERD is a condition in which acidic stomach ...

On May 5 at Digestive Disease Week a panel of nine gastroenterologists and digestive surgeons presented on radiofrequency therapy, or Stretta, as a treatment for gastroesophageal reflux disease. • ...

Phathom Pharmaceuticals (NASDAQ:PHAT) is a good biotech to keep an eye on in the coming months because it is gearing up to potentially receive an expanded FDA approval of its drug Voquenza as a daily ...

Erosive GERD approval provides Phathom $175 million under its revenue interest financing agreement Conference call and webcast scheduled for November 2, 2023, at 11:00 a.m. ET FLORHAM PARK, N.J., Nov.

Idiopathic pulmonary fibrosis (IPF) is a rapidly progressive, fatal disease of unknown cause. Although there is no known cure, there have been indications that gastroesophageal reflux disease (GERD) ...

Last month, the Food and Drug Administration (FDA) approved Voquenza Dual (vonoprazan fumarate + amoxicillin) and Triple Paks (vonoprazan fumarate + amoxicillin + clarithromycin) for the treatment of ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Have you ever felt that dreaded burning sensation in your ...

Outcomes are compared with 6-month outcomes after anterior 180° partial fundoplication, and sham procedures from trials of endoscopic therapies. No sham-controlled trial of EsophyX TIF procedure ...